INTERVENTION 1:	Intervention	0
Venetoclax + Fulvestrant	Intervention	1
venetoclax	CHEBI:133021	0-10
fulvestrant	CHEBI:31638	13-24
Participants were administered Venetoclax 800mg orally QD and Fulvestrant 500mg IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).	Intervention	2
venetoclax	CHEBI:133021	31-41
fulvestrant	CHEBI:31638	62-73
day	UO:0000033	86-89
day	UO:0000033	114-117
day	UO:0000033	160-163
length	PATO:0000122	148-154
INTERVENTION 2:	Intervention	3
Fulvestrant	Intervention	4
fulvestrant	CHEBI:31638	0-11
Participants were administered Fulvestrant 500mg only IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).	Intervention	5
fulvestrant	CHEBI:31638	31-42
day	UO:0000033	60-63
day	UO:0000033	88-91
day	UO:0000033	134-137
length	PATO:0000122	122-128
Inclusion Criteria:	Eligibility	0
Histological or cytological confirmation of estrogen receptor-positive (ER+) invasive carcinoma of the breast. ER+, HER2- negative invasive carcinoma of the breast with evaluable sample for BCL-2 IHC value at the time of screening. Participants who were originally diagnosed with HER2-positive breast cancer that converted to HER2-negative MBC are not eligible.	Eligibility	1
estrogen	CHEBI:50114,BAO:0000760	44-52
carcinoma	HP:0030731,DOID:305	86-95
carcinoma	HP:0030731,DOID:305	140-149
breast	UBERON:0000310	103-109
breast	UBERON:0000310	157-163
breast	UBERON:0000310	294-300
time	PATO:0000165	213-217
breast cancer	DOID:1612	294-307
Evidence of metastatic or locally advanced disease not amenable to surgical or local therapy with curative intent.	Eligibility	2
disease	DOID:4,OGMS:0000031	43-50
Be postmenopausal or pre- or perimenopausal women amenable to being treated with the luteinizing hormone-releasing hormone (LHRH) agonist goserelin.	Eligibility	3
hormone	CHEBI:24621	97-104
hormone	CHEBI:24621	115-122
agonist	CHEBI:48705	130-137
goserelin	CHEBI:5523	138-147
Participants must not have received more than two prior lines of hormonal therapy in the locally advanced or metastatic setting. In addition, at least one line of treatment must be a CDK4/6i AND participants must have experienced disease recurrence or progression during or after CDK4/6i therapy, which must have been administered for a minimum of 8 weeks prior to progression.	Eligibility	4
disease	DOID:4,OGMS:0000031	230-237
Participants for whom endocrine therapy (e.g., fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not indicated at the time of entry into the study, as per national or local treatment guidelines.	Eligibility	5
fulvestrant	CHEBI:31638	47-58
time	PATO:0000165	141-145
Women of childbearing potential (i.e., not postmenopausal for at least 12 months or surgically sterile) must have had a negative serum pregnancy test result at screening, within 14 days prior to the first study drug administration.	Eligibility	6
result	BAO:0000179	150-156
drug administration	OAE:0000011	211-230
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use non-hormonal contraceptive methods with a failure rate of <1% per year during the treatment period and for up to 2 years after the last dose of study drug (or based on the local prescribing information for fulvestrant). Women must refrain from donating eggs during this same period.	Eligibility	7
rate	BAO:0080019	164-168
year	UO:0000036	180-184
year	UO:0000036	229-233
drug	CHEBI:23888	264-268
fulvestrant	CHEBI:31638	320-331
Willing to provide tumor biopsy sample.	Eligibility	8
Had at least one measurable lesion via RECIST v1.1.	Eligibility	9
Had an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1.	Eligibility	10
group	CHEBI:24433	36-41
Had adequate organ and marrow function.	Eligibility	11
organ	UBERON:0000062	13-18
function	BAO:0003117,BFO:0000034	30-38
Had a life expectancy > 3 months.	Eligibility	12
To full fill the coagulation requirements for patient with or without therapeutic anticoagulation.	Eligibility	13
coagulation	GO:0050817	17-28
coagulation	GO:0050817	86-97
patient	HADO:0000008,OAE:0001817	46-53
Exclusion criteria:	Eligibility	14
Prior treatment with fulvestrant or other selective estrogen receptor degraders (SERDs), venetoclax, or any agent whose mechanism of action is to inhibit BCL-2.	Eligibility	15
fulvestrant	CHEBI:31638	21-32
estrogen	CHEBI:50114,BAO:0000760	52-60
receptor	BAO:0000281	61-69
venetoclax	CHEBI:133021	89-99
Pregnant, lactating, or intending to become pregnant during the study.	Eligibility	16
Known untreated or active Central Nervous System (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control.	Eligibility	17
active	PATO:0002354	19-25
central nervous system	UBERON:0001017	26-48
Prior chemotherapy in the locally advanced or metastatic setting regardless of the duration of the treatment.	Eligibility	18
duration	PATO:0001309	83-91
Any anti-cancer therapy received within 21 days of the first dose of study drug, including chemotherapy, radiotherapy, hormonal therapy, immunotherapy, antineoplastic vaccines, or other investigational therapy. (Radiotherapy with palliative intent to non-target sites is allowed).	Eligibility	19
drug	CHEBI:23888	75-79
radiotherapy	OAE:0000235	105-117
radiotherapy	OAE:0000235	212-224
Concurrent radiotherapy to any site or prior radiotherapy within 21 days of Cycle 1 Day 1 or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response) or prior radiotherapy to > 25% of bone marrow.	Eligibility	20
radiotherapy	OAE:0000235	11-23
radiotherapy	OAE:0000235	45-57
radiotherapy	OAE:0000235	102-114
radiotherapy	OAE:0000235	219-231
site	BFO:0000029	31-35
site	BFO:0000029	136-140
site	BFO:0000029	147-151
day	UO:0000033	68-71
day	UO:0000033	84-87
target	BAO:0003064	122-128
bone marrow	UBERON:0002371	244-255
Current severe, uncontrolled, systemic disease (e.g., clinically significant cardiovascular, pulmonary, metabolic or infectious disease.	Eligibility	21
severe	HP:0012828	8-14
disease	DOID:4,OGMS:0000031	39-46
disease	DOID:4,OGMS:0000031	128-135
Any major surgery within 28 days of the first dose of study drug or anticipation of the need for major surgery during the course of study treatment.	Eligibility	22
surgery	OAE:0000067	10-17
surgery	OAE:0000067	103-110
drug	CHEBI:23888	60-64
Consumption of one or more of the following within 3 days prior to the first dose of study drug: Grapefruit or grapefruit products; Seville oranges including marmalade containing Seville oranges; Star fruit (carambola).	Eligibility	23
drug	CHEBI:23888	91-95
Administration within 7 days prior first dose of study treatment of Steroid therapy for anti-neoplastic intent, Strong or moderate CYP3A inhibitors or Strong or moderate CYP3A inducers.	Eligibility	24
steroid	CHEBI:35341	68-75
moderate	HP:0012826	122-130
moderate	HP:0012826	161-169
Need for current chronic corticosteroid therapy (> 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids).	Eligibility	25
chronic	HP:0011010	17-24
corticosteroid	CHEBI:50858	25-39
corticosteroid	CHEBI:50858	128-142
prednisone	CHEBI:8382	60-70
day	UO:0000033	75-78
Known infection with (human immunodeficiency virus) HIV or human T-cell leukemia virus 1.	Eligibility	26
immunodeficiency	HP:0002721	28-44
virus	BAO:0000232	45-50
virus	BAO:0000232	81-86
leukemia	HP:0001909,DOID:1240	72-80
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day).	Eligibility	27
active	PATO:0002354	6-12
nail	UBERON:0001705	116-120
day	UO:0000033	331-334
Positive test results for hepatitis B core antibody (HBcAb) or hepatitis C virus (HCV) antibody at screening. Participants who were positive for HCV antibody should have been negative for HCV by PCR to be eligible for study participation. Participants with a past or resolved hepatitis B virus (HBV) infection (defined as having a positive total HBcAb and negative hepatitis B surface antigen [HbsAg]) may be included if HBV DNA is undetectable. These participants should have been willing to undergo monthly DNA testing.	Eligibility	28
hepatitis b	DOID:2043	26-37
hepatitis b	DOID:2043	276-287
hepatitis b	DOID:2043	365-376
antibody	GO:0042571,BAO:0000502	43-51
antibody	GO:0042571,BAO:0000502	87-95
antibody	GO:0042571,BAO:0000502	149-157
hepatitis c	DOID:1883	63-74
virus	BAO:0000232	75-80
virus	BAO:0000232	288-293
antigen	CHEBI:59132	385-392
dna	BAO:0000269	425-428
dna	BAO:0000269	509-512
Participants who had a positive HCV antibody test are eligible for the study if a PCR assay is negative for HCV RNA.	Eligibility	29
antibody	GO:0042571,BAO:0000502	36-44
rna	BAO:0000270	112-115
History of other malignancies within the past 5 years except for treated skin basal cell carcinoma, squamous cell carcinoma, non-malignant melanoma <= 1.0 mm without ulceration, localized thyroid cancer, or cervical carcinoma in-situ.	Eligibility	30
history	BFO:0000182	0-7
basal cell carcinoma	HP:0002671,DOID:2513	78-98
squamous cell carcinoma	HP:0002860,DOID:1749	100-123
melanoma	HP:0002861,DOID:1909	139-147
localized	HP:0012838,PATO:0000627	178-187
cancer	DOID:162	196-202
carcinoma	HP:0030731,DOID:305	89-98
carcinoma	HP:0030731,DOID:305	114-123
carcinoma	HP:0030731,DOID:305	216-225
Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study.	Eligibility	31
vaccine	VO:0000001	37-44
vaccine	VO:0000001	134-141
Cardiopulmonary dysfunction.	Eligibility	32
Other medical or psychiatric conditions that, in the opinion of the investigatory, may interfere with the participant's participation in the study.	Eligibility	33
Inability or unwillingness to swallow pills or receive intramuscular (IM) injections.	Eligibility	34
History of malabsorption syndrome or other condition that would interfere with enteral absorption.	Eligibility	35
history	BFO:0000182	0-7
malabsorption	HP:0002024	11-24
syndrome	DOID:225	25-33
condition	PDRO:0000129	43-52
History of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or active bowel inflammation (e.g., diverticulitis).	Eligibility	36
history	BFO:0000182	0-7
inflammatory bowel disease	DOID:0050589	11-37
disease	DOID:4,OGMS:0000031	30-37
disease	DOID:4,OGMS:0000031	53-60
ulcerative colitis	HP:0100279,DOID:8577	64-82
active	PATO:0002354	87-93
diverticulitis	DOID:7475	120-134
Concurrent hormone replacement therapy.	Eligibility	37
hormone	CHEBI:24621	11-18
Inability to comply with study and follow-up procedures.	Eligibility	38
History or active cardiopulmonary dysfunction.	Eligibility	39
history	BFO:0000182	0-7
active	PATO:0002354	11-17
Known hypersensitivity to any of the study medications (fulvestrant, venetoclax) or to any of the excipients.	Eligibility	40
hypersensitivity	GO:0002524,DOID:1205	6-22
fulvestrant	CHEBI:31638	56-67
venetoclax	CHEBI:133021	69-79
Outcome Measurement:	Results	0
Clinical Benefit Defined as Complete Response (CR), Partial Response (PR) or Stable Disease (SD) Lasting >= 24 Weeks, as Determined by the Investigator According to RECIST v1.1	Results	1
stable	HP:0031915	77-83
disease	DOID:4,OGMS:0000031	84-91
Clinical Benefit was defined as CR, PR, or SD lasting more than equal to 24 weeks from randomization in participants with measurable disease at baseline, as determined by the investigator according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions assessed by CT or MRI: CR, Disappearance of all target lesions; PR, PR >= 30% decrease in the sum of diameters of target lesions (TL) taking as reference the baseline sum of diameters; SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Disease Progression (PD), PD>= 20% increase in the sum of diameters of TL taking as reference the smallest sum on study(Nadir). In addition to the relative increase of 20% sum must have demonstrate an absolute increase of at least 5mm.	Results	2
disease	DOID:4,OGMS:0000031	133-140
disease	DOID:4,OGMS:0000031	580-587
target	BAO:0003064	290-296
target	BAO:0003064	353-359
target	BAO:0003064	419-425
ct	BAO:0002125	317-319
increase	BAO:0001251	556-564
increase	BAO:0001251	615-623
increase	BAO:0001251	736-744
increase	BAO:0001251	790-798
Time frame: Randomization through till 6 months after the last participant is enrolled into the study (up to approximately 23 months)	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Venetoclax + Fulvestrant	Results	5
venetoclax	CHEBI:133021	17-27
fulvestrant	CHEBI:31638	30-41
Arm/Group Description: Participants were administered Venetoclax 800mg orally QD and Fulvestrant 500mg IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).	Results	6
venetoclax	CHEBI:133021	54-64
fulvestrant	CHEBI:31638	85-96
day	UO:0000033	109-112
day	UO:0000033	137-140
day	UO:0000033	183-186
length	PATO:0000122	171-177
Overall Number of Participants Analyzed: 51	Results	7
Measure Type: Number	Results	8
Unit of Measure: Percentage of Participants  11.8        (4.44 to 23.87)	Results	9
Results 2:	Results	10
Arm/Group Title: Fulvestrant	Results	11
fulvestrant	CHEBI:31638	17-28
Arm/Group Description: Participants were administered Fulvestrant 500mg only IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).	Results	12
fulvestrant	CHEBI:31638	54-65
day	UO:0000033	83-86
day	UO:0000033	111-114
day	UO:0000033	157-160
length	PATO:0000122	145-151
Overall Number of Participants Analyzed: 51	Results	13
Measure Type: Number	Results	14
Unit of Measure: Percentage of Participants  13.7        (5.70 to 26.26)	Results	15
Adverse Events 1:	Adverse Events	0
Total: 4/50 (8.00%)	Adverse Events	1
Pyrexia 1/50 (2.00%)	Adverse Events	2
Lower respiratory tract infection 1/50 (2.00%)	Adverse Events	3
lower respiratory tract	UBERON:0001558	0-23
respiratory tract infection	HP:0011947	6-33
Urosepsis 1/50 (2.00%)	Adverse Events	4
Ejection fraction decreased 1/50 (2.00%)	Adverse Events	5
ejection fraction	CMO:0000180	0-17
Flank pain 0/50 (0.00%)	Adverse Events	6
flank pain	HP:0030157	0-10
Bone pain 0/50 (0.00%)	Adverse Events	7
bone pain	HP:0002653	0-9
Pleural effusion 0/50 (0.00%)	Adverse Events	8
pleural effusion	HP:0002202	0-16
Adverse Events 2:	Adverse Events	9
Total: 2/51 (3.92%)	Adverse Events	10
Pyrexia 0/51 (0.00%)	Adverse Events	11
Lower respiratory tract infection 0/51 (0.00%)	Adverse Events	12
lower respiratory tract	UBERON:0001558	0-23
respiratory tract infection	HP:0011947	6-33
Urosepsis 0/51 (0.00%)	Adverse Events	13
Ejection fraction decreased 0/51 (0.00%)	Adverse Events	14
ejection fraction	CMO:0000180	0-17
Flank pain 1/51 (1.96%)	Adverse Events	15
flank pain	HP:0030157	0-10
Bone pain 1/51 (1.96%)	Adverse Events	16
bone pain	HP:0002653	0-9
Pleural effusion 1/51 (1.96%)	Adverse Events	17
pleural effusion	HP:0002202	0-16
